Neogen Corporation Excess Tax Benefit from Share-based Compensation, Operating Activities
Neogen Corporation (NEOG) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $3.92 million for the 12-month period ending 2017-05-31, per its 10-K filed 2019-07-30.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2019-07-30
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2017-05-31 was $251.00K, a 1.57% decline year-over-year.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2017-02-28 was $1.20M, a 383.81% increase year-over-year.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-11-30 was $1.75M, a 210.48% increase year-over-year.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-08-31 was $728.00K, a 61.28% decline year-over-year.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2017 was $3.92M, a 33.17% increase from fiscal 2016.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2016 was $2.94M, a 18.99% increase from fiscal 2015.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2015 was $2.48M, a 47.97% decline from fiscal 2014.
- Neogen Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2014 was $4.76M, a 52.81% increase from fiscal 2013.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month |
|---|---|---|---|---|
| 2017-05-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-07-30 | $1.45M derived: sum of 2 quarters · filed 2019-07-30 | $3.19M derived: sum of 3 quarters · filed 2019-07-30 | $3.92M 10-K · filed 2019-07-30 |
| 2017-02-28 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-29 | $2.94M derived: sum of 2 quarters · filed 2018-03-29 | $3.67M 10-Q · filed 2018-03-29 | $3.93M derived: sum of 4 quarters · filed 2018-07-27 |
| 2016-11-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-01-05 | $2.48M 10-Q · filed 2018-01-05 | $2.73M derived: sum of 3 quarters · filed 2018-07-27 | $2.98M derived: sum of 4 quarters · filed 2018-07-27 |
| 2016-08-31 | $728.00K 10-Q · filed 2017-09-29 | $983.00K derived: sum of 2 quarters · filed 2018-07-27 | $1.23M derived: sum of 3 quarters · filed 2018-07-27 | $1.79M derived: sum of 4 quarters · filed 2018-07-27 |
| 2016-05-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-27 | $502.00K derived: sum of 2 quarters · filed 2018-07-27 | $1.06M derived: sum of 3 quarters · filed 2018-07-27 | $2.94M 10-K · filed 2018-07-27 |
| 2016-02-29 | $247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-03-31 | $810.00K derived: sum of 2 quarters · filed 2017-03-31 | $2.69M 10-Q · filed 2017-03-31 | $3.49M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-11-30 | $563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-12-29 | $2.44M 10-Q · filed 2016-12-29 | $3.25M derived: sum of 3 quarters · filed 2017-07-28 | $3.79M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-08-31 | $1.88M 10-Q · filed 2016-09-30 | $2.68M derived: sum of 2 quarters · filed 2017-07-28 | $3.22M derived: sum of 3 quarters · filed 2017-07-28 | $3.49M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-05-31 | $803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | $1.34M derived: sum of 2 quarters · filed 2017-07-28 | $1.61M derived: sum of 3 quarters · filed 2017-07-28 | $2.48M 10-K · filed 2017-07-28 |
| 2015-02-28 | $540.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-31 | $807.00K derived: sum of 2 quarters · filed 2016-03-31 | $1.67M 10-Q · filed 2016-03-31 | $2.48M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-11-30 | $267.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-08 | $1.13M 10-Q · filed 2016-01-08 | $1.94M derived: sum of 3 quarters · filed 2016-07-29 | $3.78M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-08-31 | $865.00K 10-Q · filed 2015-09-30 | $1.67M derived: sum of 2 quarters · filed 2016-07-29 | $3.52M derived: sum of 3 quarters · filed 2016-07-29 | $4.04M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-05-31 | $809.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29 | $2.65M derived: sum of 2 quarters · filed 2016-07-29 | $3.17M derived: sum of 3 quarters · filed 2016-07-29 | $4.76M 10-K · filed 2016-07-29 |
| 2014-02-28 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-01 | $2.36M derived: sum of 2 quarters · filed 2015-04-01 | $3.95M 10-Q · filed 2015-04-01 | $5.19M derived: sum of 4 quarters · filed 2015-07-30 |
| 2013-11-30 | $522.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-30 | $2.11M 10-Q · filed 2014-12-30 | $3.35M derived: sum of 3 quarters · filed 2015-07-30 | $3.72M derived: sum of 4 quarters · filed 2015-07-30 |
| 2013-08-31 | $1.58M 10-Q · filed 2014-09-30 | $2.83M derived: sum of 2 quarters · filed 2015-07-30 | $3.20M derived: sum of 3 quarters · filed 2015-07-30 | $3.67M derived: sum of 4 quarters · filed 2015-07-30 |
| 2013-05-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-30 | $1.61M derived: sum of 2 quarters · filed 2015-07-30 | $2.08M derived: sum of 3 quarters · filed 2015-07-30 | $3.11M 10-K · filed 2015-07-30 |
| 2013-02-28 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-04-04 | $839.00K derived: sum of 2 quarters · filed 2014-04-04 | $1.87M 10-Q · filed 2014-04-04 | $2.27M derived: sum of 4 quarters · filed 2014-07-30 |
| 2012-11-30 | $471.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-01-09 | $1.50M 10-Q · filed 2014-01-09 | $1.90M derived: sum of 3 quarters · filed 2014-07-30 | $1.97M derived: sum of 4 quarters · filed 2014-07-30 |
| 2012-08-31 | $1.03M 10-Q · filed 2013-09-30 | $1.43M derived: sum of 2 quarters · filed 2014-07-30 | $1.49M derived: sum of 3 quarters · filed 2014-07-30 | $2.30M derived: sum of 4 quarters · filed 2014-07-30 |
| 2012-05-31 | $397.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-07-30 | $465.00K derived: sum of 2 quarters · filed 2014-07-30 | $1.27M derived: sum of 3 quarters · filed 2014-07-30 | $1.83M 10-K · filed 2014-07-30 |
| 2012-02-29 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-03-28 | $876.00K derived: sum of 2 quarters · filed 2013-03-28 | $1.43M 10-Q · filed 2013-03-28 | $3.96M derived: sum of 4 quarters · filed 2013-07-30 |
| 2011-11-30 | $808.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-12-28 | $1.36M 10-Q · filed 2012-12-28 | $3.90M derived: sum of 3 quarters · filed 2013-07-30 | $4.03M derived: sum of 4 quarters · filed 2013-07-30 |
| 2011-08-31 | $556.00K 10-Q · filed 2012-09-28 | $3.09M derived: sum of 2 quarters · filed 2013-07-30 | $3.23M derived: sum of 3 quarters · filed 2013-07-30 | $3.39M derived: sum of 4 quarters · filed 2013-07-30 |
| 2011-05-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2013-07-30 | $2.67M derived: sum of 2 quarters · filed 2013-07-30 | $2.84M derived: sum of 3 quarters · filed 2013-07-30 | $2.99M 10-K · filed 2013-07-30 |
| 2011-02-28 | $139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-03-30 | $306.00K derived: sum of 2 quarters · filed 2012-03-30 | $461.00K 10-Q · filed 2012-03-30 | |
| 2010-11-30 | $167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-12-30 | $322.00K 10-Q · filed 2011-12-30 | ||
| 2010-08-31 | $155.00K 10-Q · filed 2011-09-30 | |||
| 2010-05-31 | $709.00K 10-K · filed 2012-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |